Dr. Cantley is a founder of Agios, a biopharmaceutical company dedicated to the discovery and development of novel medicines in the emerging field of cancer metabolism and rare genetic disorders of metabolism.
The mission of the American Association for Cancer Research (AACR) is to prevent and cure cancer through research, education, communication, and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science, accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer, promotes science education and training, and advances the understanding of cancer etiology, prevention, diagnosis and treatment throughout the world. Dr. Cantley is an AACR Academy Fellow and member of its Board of Directors. He is active in organizing conferences and other activities, and is also co-editor of the AACR journal Cancer Discovery.
The Institute for Precision Medicine at Weill Cornell Medical College and NewYork-Presbyterian Hospital is a translational research hub, which opened under the direction of renowned pathologist and prostate cancer expert Dr. Mark Rubin in 2013. The IPM team includes clinicians, basic scientists, pathologists, molecular biologists and computational biologists. These physician-scientists are directing their collective expertise and wealth of knowledge to identify the molecular underpinnings of disease and spur the discovery of novel therapies.
The Meyer Cancer Center is a collaborative, multidisciplinary research enterprise located at Weill Cornell Medical College, in affiliation with NewYork-Presbyterian Hospital. Equipped with the latest state-of-the-art technologies, nearly 250 basic, translational and clinical researchers from Weill Cornell and Cornell University’s Ithaca campus work together with colleagues at other institutions – including Memorial Sloan Kettering, Columbia University, Rockefeller University and New York Methodist Hospital – to take fundamental discoveries from bench to bedside, and back again. The Center’s mission is to ensure that patients can have immediate access to emerging new therapies in a supportive and caring environment, while training future researchers and recruiting leaders in cancer research and clinical care.
Additional news and information about clinical trials associated with the lab and the Stand Up To Cancer PI3k Dream Team.
Dr. Cantley led the multi-institutional PI3K Dream Team for Stand Up To Cancer. The $15 million, four-year project focused on targeting the PI3K pathway in women's cancers. Dozens of drugs targeting PI3K and interacting pathways have been tested in 57 breast cancer cell lines, 54 ovarian cancer cell lines and 37 endometrial cancer cell lines to identify potentially novel biomarkers, in conjunction with clinical trials of novel combination drug therapies.